Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA

MaaT Pharma’s 18-month struggle to get out from under an FDA clinical hold may be entering its endgame. In its latest feedback, the agency reportedly agreed to a list of conditions that could enable clinical evaluation of the company's pooled fecal therapy MaaT013 in the U.S.